...
首页> 外文期刊>Cancer biology & therapy >Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential
【24h】

Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential

机译:胶质母细胞瘤干细胞样细胞的分化导致EGFR和EGFRvIII的下调并降低致瘤和干细胞样细胞的潜能

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Glioblastoma multiforme (GBM) is the most common and devastating primary brain tumor among adults. Despite recent treatment progress, most patients succumb to their disease within 2 years of diagnosis. Current research has highlighted the importance of a subpopulation of cells, assigned brain cancer stem-like cells (bCSC), to play a pivotal role in GBM malignancy. bCSC are identified by their resemblance to normal neural stem cells (NSC), and it is speculated that the bCSC have to be targeted in order to improve treatment outcome for GBM patients. One hallmark of GBM is aberrant expression and activation of the epidermal growth factor receptor (EGFR) and expression of a deletion variant EGFRvIII. In the normal brain, EGFR is expressed in neurogenic areas where also NSC are located and it has been shown that EGFR is involved in regulation of NSC proliferation, migration, and differentiation. This led us to speculate if EGFR and EGFRvIII are involved in the regulation of bCSC. In this study we use GBM neurosphere cultures, known to preserve bCSC features. We demonstrate that EGFR and EGFRvIII are downregulated upon differentiation and moreover that when EGFR signaling is abrogated, differentiation is induced. Furthermore, we show that differentiation leads to decreased tumorigenic and stem cell-like potential of the neurosphere cultures and that by specifically inhibiting EGFR signaling it is possible to target the bCSC population. Our results suggest that differentiation therapy, possibly along with anti-EGFR treatment would be a feasible treatment option for patients with GBM, by targeting the bCSC population.
机译:多形胶质母细胞瘤(GBM)是成年人中最常见和最具破坏性的原发性脑肿瘤。尽管最近的治疗取得了进展,但大多数患者在诊断后的两年内就屈服于自己的疾病。当前的研究突出了分配给脑癌干细胞样细胞(bCSC)的细胞亚群在GBM恶性肿瘤中起关键作用的重要性。通过与正常神经干细胞(NSC)相似来鉴定bCSC,并且推测必须靶向bCSC才能改善GBM患者的治疗效果。 GBM的一个标志是表皮生长因子受体(EGFR)的异常表达和激活以及缺失变体EGFRvIII的表达。在正常脑中,EGFR在神经源性区域(也位于NSC中)表达,并且已经证明EGFR参与NSC增殖,迁移和分化的调节。这使我们推测EGFR和EGFRvIII是否参与bCSC的调控。在这项研究中,我们使用GBM神经球培养物,已知能保留bCSC功能。我们证明,分化后EGFR和EGFRvIII被下调,此外,当EGFR信号被废除时,诱导分化。此外,我们显示分化导致神经球培养物的致瘤和干细胞样潜能降低,并且通过特异性抑制EGFR信号传导,有可能靶向bCSC群体。我们的结果表明,通过靶向bCSC人群,分化疗法,可能与抗EGFR治疗一起可能是GBM患者的可行治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号